Company news

Halozyme Therapeutics, Inc. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Halozyme to Report Second Quarter 2025 Financial and Operating Results

July 21, 2025

Halozyme Therapeutics Added to Russell 1000® Index

June 29, 2025

Halozyme Announces argenx Received European Commission Approval for VYVGART® Subcutaneous Injection with ENHANZE® for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

June 19, 2025

Halozyme Announces Bristol Myers Squibb Received European Commission Approval for Subcutaneous Opdivo® (nivolumab) Co-Formulated with ENHANZE® Across Multiple Solid Tumor Indications

May 27, 2025

Halozyme raises 2025 financial guidance ranges and reports strong first quarter 2025 results

May 5, 2025

Halozyme to Participate in the BofA Securities 2025 Healthcare Conference

May 4, 2025

Halozyme to Report First Quarter 2025 Financial and Operating Results

April 27, 2025

Halozyme Announces argenx Received Positive CHMP Opinion for VYVGART® (efgartigimod alfa) Subcutaneous Injection with ENHANZE® for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

April 27, 2025

Halozyme Sues Merck for Patent Infringement over Subcutaneous Keytruda Formulation

April 23, 2025

Halozyme Announces FDA Approval of argenx's VYVGART® Hytrulo Prefilled Syringe Co-Formulated with ENHANZE® for Self-Injection for Generalized Myasthenia Gravis and Chronic Inflammatory Demyelinating Polyneuropathy

April 9, 2025

European Commission Approved Subcutaneous DARZALEX® (daratumumab)-based Quadruplet Regimen for the Treatment of Patients with Newly Diagnosed Multiple Myeloma, Regardless of Transplant Eligibility

April 8, 2025

European Commission Approves Subcutaneous RYBREVANT® (amivantamab) Co-Formulated with ENHANZE® for the Treatment of Patients with Advanced EGFR-Mutated Non-Small Cell Lung Cancer

April 6, 2025

Halozyme Announces Bristol Myers Squibb Received Positive CHMP Opinion for the Subcutaneous Formulation of Opdivo® (nivolumab) with ENHANZE® Across Multiple Solid Tumor Indications

March 30, 2025

Halozyme to Participate in the TD Cowen 45th Annual Healthcare Conference

February 25, 2025

Halozyme reports full year 2024 record revenue of $1.015 billion and exceeds its financial guidance for royalty revenue, adjusted EBITDA and non-GAAP diluted EPS

February 17, 2025

Halozyme to Report Fourth Quarter and Full Year 2024 Financial and Operating Results

February 3, 2025

CHMP Issues Positive Opinion for Subcutaneous RYBREVANT®(amivantamab) Co-Formulated with ENHANZE® for the Treatment of Patients with Advanced EGFR-Mutated Non-Small Cell Lung Cancer

February 2, 2025

Halozyme Reiterates 2024 Financial Guidance and Raises 2025 and Multi-Year Financial Guidance

January 7, 2025

Halozyme to Host Investor Conference Call to Provide Updated 2025 Financial Guidance

January 5, 2025

Halozyme Announces Takeda Received Regulatory Approval for HYQVIA® 10% Subcutaneous Injection Set with ENHANZE® in Japan for Patients with Agammaglobulinemia or Hypogammaglobulinemia

December 29, 2024

Halozyme Announces FDA Approval of Bristol Myers Squibb's Opdivo Qvantig™ with ENHANZE® for Subcutaneous Use in Most Previously Approved Adult Solid Tumor Opdivo® (nivolumab) Indications

December 29, 2024

Halozyme Announces argenx's VYDURA with ENHANZE® was Granted Regulatory Approval in Japan for Chronic Inflammatory Demyelinating Polyneuropathy

December 29, 2024

Halozyme to Present at Upcoming Investor Conferences

November 26, 2024

Halozyme Withdraws Proposal to Acquire Evotec Following Evotec's Unwillingness to Engage in Discussions

November 21, 2024

Halozyme Provides Update on Non-Binding Proposal to Combine with Evotec

November 17, 2024

Halozyme Confirms Proposal to Combine with Evotec for €11.00 Per Share in an All-Cash Transaction

November 13, 2024

Halozyme reports third quarter 2024 financial and operating results

October 30, 2024

Halozyme provides update on licensee co-formulation patent hearing in Europe

October 23, 2024

Halozyme to Report Third Quarter 2024 Financial and Operating Results

October 22, 2024

Halozyme Announces Expansion of Global Collaboration and License Agreement with argenx for ENHANZE®

October 2, 2024

Halozyme Announces FDA Approval of Roche's Subcutaneous OCREVUS ZUNOVO™ with ENHANZE® for People with Relapsing and Primary Progressive Multiple Sclerosis

September 12, 2024

Halozyme Announces FDA Approval of Roche's Tecentriq Hybreza™ With ENHANZE® for Multiple Types of Cancer

September 11, 2024

Halozyme reports second quarter 2024 financial and operating results

August 5, 2024

Halozyme to Report Second Quarter 2024 Financial and Operating Results

July 22, 2024

Halozyme Announces Roche's OCREVUS® SC with ENHANZE® Receives European Commission Approval for Relapsing and Primary Progressive Multiple Sclerosis

June 24, 2024

Halozyme Announces argenx Receives FDA Approval for VYVGART® Hytrulo Co-Formulated with ENHANZE® for Chronic Inflammatory Demyelinating Polyneuropathy

June 20, 2024

Halozyme Raises Full Year 2024 Financial Guidance and Updates 5-Year Financial Outlook

June 5, 2024

Halozyme Announces Issuance of New European Patent for ENHANZE® Drug Delivery Platform

June 4, 2024

Halozyme to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference

June 3, 2024

Halozyme Announces Bristol Myers Squibb Received Updated Action Date from the U.S. Food and Drug Administration for Subcutaneous Nivolumab Co-Formulated with ENHANZE®

May 20, 2024

Halozyme to Participate in Upcoming Investor Conferences

May 7, 2024

Halozyme reports first quarter 2024 financial and operating results

May 6, 2024

Mahesh Krishnan Elected to Halozyme's Board of Directors

April 24, 2024

Halozyme to Report First Quarter 2024 Financial and Operating Results

April 22, 2024

Halozyme reports fourth quarter and full year 2023 financial and operating results

February 19, 2024

Halozyme To Report Fourth Quarter and Full Year 2023 Financial and Operating Results

February 7, 2024

Halozyme Announces Takeda Received European Commission Approval for HYQVIA® Co-formulated with ENHANZE® as Maintenance Therapy for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

January 28, 2024

Halozyme Announces argenx Received Approval in Japan for VYVDURA® (efgartigimod alfa and hyaluronidase-qvfc) Co-Formulated with ENHANZE® for Generalized Myasthenia Gravis

January 17, 2024

Halozyme Announces Takeda Receives FDA Approval for HYQVIA® Co-formulated with ENHANZE® as Maintenance Therapy in Adults with Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

January 15, 2024

Halozyme Announces Roche Receives European Commission Approval of Tecentriq® SC with ENHANZE® Representing the EU's First Subcutaneous PD-(L)1 Cancer Immunotherapy for Multiple Cancer Types

January 15, 2024

← Newer news releases · Older news releases →

Calls

The 5 newest of 27 calls. Every call is listed under its year.

Decks

The 5 newest of 63 decks. Every deck is listed under its year.